Bioxytran (BIXT) 10-Q13 Nov 202020 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2020	Nov. 12, 2020
Cover [Abstract]
Entity Registrant Name	BIOXYTRAN, INC
Entity Central Index Key	0001445815
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		97,187,673
Entity File Number	001-35027
Entity Incorporation State Country Code	NV

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 633	$ 169,628
Other receivable		50,000
Total current assets	633	219,628
Total assets	633	219,628
Current liabilities:
Accounts payable and accrued expenses	221,057	71,932
Accounts payable related party	259,135	96,000
Loan payable	8,115
Convertible notes payable, net of premium and discount	1,604,856	850,983
Total current liabilities	2,093,163	1,018,915
Total liabilities	2,093,163	1,018,915
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 50,000,000 shares authorized, nil issued and outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized; 97,184,673 issued and outstanding as of September 30, 2020, and 86,475,673 issued and outstanding as of December 31, 2019	97,185	86,476
Additional paid-in capital	1,722,724	1,355,542
Accumulated deficit	(3,912,439)	(2,241,305)
Total stockholders' equity (deficit)	(2,092,530)	(799,287)
Total liabilities and stockholders' equity (deficit)	$ 633	$ 219,628

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	97,184,673	86,475,673
Common stock, shares outstanding	97,184,673	86,475,673

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
General and administrative	$ 114,448	$ 850,319	$ 492,400	$ 1,131,803
Total operating expenses	114,448	850,319	492,400	1,131,803
Loss from operations	(114,448)	(850,319)	(492,400)	(1,131,803)
Other (expenses):
Interest expense	(86,593)	(10,002)	(919,677)	(26,891)
Amortization of debt discount, incl issuance of warrants	(1,000)	(13,794)	(259,057)	(37,124)
Total other (expenses)	(87,593)	(23,796)	(1,178,734)	(64,015)
Net loss before provision for income taxes	(202,041)	(874,115)	(1,671,134)	(1,195,818)
Provision for income taxes
NET LOSS	$ (202,041)	$ (874,115)	$ (1,671,134)	$ (1,195,818)
Loss per common share, basic and diluted	$ 0	$ (0.01)	$ 0	$ (0.01)
Weighted average number of common shares outstanding, basic and diluted	97,105,293	85,198,032	92,169,035	85,138,310

CONDENSED CONSOLIDATED CHANGES

CONDENSED CONSOLIDATED CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($)	Common Stock [Member]	Additional Paid in Capital Common [Member]	Accumulated Deficit [Member]	Total
Balance at beginning at Dec. 31, 2018	$ 85,104	$ 72,412	$ (382,830)	$ (225,314)
Balance at beginning (in shares) at Dec. 31, 2018	85,103,673
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of warrants		45,361		45,361
Debt premium on convertible note		(343,796)		(343,796)
Debt premium accretion		60,268		60,268
Net loss			(191,409)	(191,409)
Balance at ending at Mar. 31, 2019	$ 85,104	(165,755)	(574,239)	(654,890)
Balance at ending (in shares) at Mar. 31, 2019	85.103673
Balance at beginning at Dec. 31, 2018	$ 85,104	72,412	(382,830)	(225,314)
Balance at beginning (in shares) at Dec. 31, 2018	85,103,673
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of warrants				45,361
Balance at ending at Sep. 30, 2019	$ 85,307	312,701	(1,578,648)	(1,180,640)
Balance at ending (in shares) at Sep. 30, 2019	85,306,673
Balance at beginning at Mar. 31, 2019	$ 85,104	(165,755)	(574,239)	(654,890)
Balance at beginning (in shares) at Mar. 31, 2019	85.103673
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Debt premium accretion		123,276		123,276
Shares issued for conversion of principal and accrued interest	$ 25	4,975		5,000
Shares issued for conversion of principal and accrued interest, shares	25,000
Net loss			(130,294)	(130,294)
Balance at ending at Jun. 30, 2019	$ 85,129	(37,504)	(704,533)	(656,908)
Balance at ending (in shares) at Jun. 30, 2019	85,128,673
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options issued and vested - 2010 Plan		228,058		228,058
Shares issued to BoD - 2010 Plan	$ 108	34,492		34,600
Shares issued to BoD - 2010 Plan, shares	108,000
Debt premium on convertible note		(82,500)		(82,500)
Debt premium accretion		140,225		140,225
Shares issued for conversion of principal and accrued interest	$ 50	9,950		10,000
Shares issued for conversion of principal and accrued interest, shares	50,000
Shares issued for cash	$ 20	19,980		20,000
Shares issued for cash, shares	20,000
Net loss			(874,115)	(874,115)
Balance at ending at Sep. 30, 2019	$ 85,307	312,701	(1,578,648)	(1,180,640)
Balance at ending (in shares) at Sep. 30, 2019	85,306,673
Balance at beginning at Dec. 31, 2019	$ 86,476	1,355,542	(2,241,305)	(799,287)
Balance at beginning (in shares) at Dec. 31, 2019	86,475,673
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of warrants		145,438		145,438
Exercise of warrants	$ 750	(750)
Exercise of warrants, shares	750,000
Options issued and vested - 2010 Plan		5,004		5,004
Shares issued to BoD - 2010 Plan	$ 656	149,841		150,497
Shares issued to BoD - 2010 Plan, shares	656,000
Debt premium on convertible note		(937,007)		(937,007)
Debt premium accretion		104,568		104,568
Shares issued for conversion of principal and accrued interest	$ 350	33,782		34,132
Shares issued for conversion of principal and accrued interest, shares	350,000
Net loss			(540,495)	(540,495)
Balance at ending at Mar. 31, 2020	$ 88,232	856,418	(2,781,800)	(1,837,150)
Balance at ending (in shares) at Mar. 31, 2020	88,231,673
Balance at beginning at Dec. 31, 2019	$ 86,476	1,355,542	(2,241,305)	(799,287)
Balance at beginning (in shares) at Dec. 31, 2019	86,475,673
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of warrants				145,438
Balance at ending at Sep. 30, 2020	$ 97,185	1,722,724	(3,912,439)	(2,092,530)
Balance at ending (in shares) at Sep. 30, 2020	97,184,673
Balance at beginning at Mar. 31, 2020	$ 88,232	856,418	(2,781,800)	(1,837,150)
Balance at beginning (in shares) at Mar. 31, 2020	88,231,673
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options issued and vested - 2010 Plan		691		691
Shares issued to BoD - 2010 Plan	$ 8,800			8,800
Shares issued to BoD - 2010 Plan, shares	8,800,000
Debt premium accretion		856,560		856,560
Net loss			(928,598)	(928,598)
Balance at ending at Jun. 30, 2020	$ 97,032	1,713,669	(3,710,398)	(1,899,697)
Balance at ending (in shares) at Jun. 30, 2020	97,031,673
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options issued and vested - 2010 Plan		6,838		6,838
Shares issued to BoD - 2010 Plan	$ 3	567		570
Shares issued to BoD - 2010 Plan, shares	3,000
Shares issued to Consultants - 2010 Plan	$ 150	1,650		1,800
Shares issued to Consultants - 2010 Plan, shares	150,000
Net loss			(202,041)	(202,041)
Balance at ending at Sep. 30, 2020	$ 97,185	$ 1,722,724	$ (3,912,439)	$ (2,092,530)
Balance at ending (in shares) at Sep. 30, 2020	97,184,673

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,671,134)	$ (1,195,818)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt discount, incl. issuance of warrants	259,057	37,124
Default fee convertible notes	666,456
Stock-based compensation expense	174,200	840,438
Changes in operating assets and liabilities:
Other receivable	50,000
Accounts payable and accrued expenses	150,125	83,721
Accounts payable related party	163,135	(10,900)
Net cash used in operating activities	(208,161)	(245,435)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Loan	8,114
Proceeds from sale of common stock		20,000
Proceeds from issuance of convertible notes payable	264,000	222,250
Repayment of convertible notes payable	(232,948)
Net cash provided by financing activities	39,166	242,250
Net increase (decrease) in cash	(168,995)	(3,185)
Cash, beginning of period	169,628	36,411
Cash, end of period	633	33,226
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	91,362
Income taxes paid
NON-CASH INVESTING & FINANCING ACTIVITIES
Issuance of warrants	145,438	45,361
Debt discount on convertible note		(27,042)
Debt premium on convertible note	(937,007)	426,296
Accretion of debt premium to additional paid-in capital	961,128	(323,769)
Common shares issued for the conversion of principal and accrued interest	$ 34,132	$ 15,000

BACKGROUND AND ORGANIZATION

BACKGROUND AND ORGANIZATION	9 Months Ended
BACKGROUND AND ORGANIZATION	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND AND ORGANIZATION	NOTE 1 – BACKGROUND AND ORGANIZATION Business Operations Bioxytran, Inc. (the “Company”) is an early-stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner. If it is not addressed, lack of oxygen to tissues, or hypoxia, results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications to include treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company’s initial focus is the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. Our novel approach is intended to result in the creation of safe drug alternatives to existing therapies for effectively addressing hypoxic conditions in humans. Our drug development efforts are guided by specialists in co-polymer chemistry and other disciplines, and we intend to supplement our efforts with input from a scientific and medical advisory board whose members are leading physicians. Organization Bioxytan, Inc. was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized common shares with a par value of $0.0001, and 5,000,000 preferred shares with a par value of $0.0001. On September 21, 2019, the Company went under a reorganization in form of a reverse merger and is currently registered as a Nevada corporation with a taxing structure for U.S. federal and state income tax as a C-Corporation with 300,000,000 authorized common shares with a par value of $0.001, and 50,000,000 preferred shares with a par value of $0.001 Basis of Presentation The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America (“U.S. GAAP”) in all material respects, and have been consistently applied in preparing the accompanying financial statements. The Company has not earned any revenue from operations since inception. The Company chose December 31 st The accompanying unaudited financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"), including the instructions to Form 10-Q and Regulation S-X Basic and Diluted Earnings per Share Pursuant to the authoritative guidance, basic net income and net loss per share are computed by dividing the net income and net loss by the weighted average number of common shares outstanding. Diluted net income and net loss per share is the same as basic net income and net loss per share when their inclusion would have an anti-dilutive effect due to our continuing net losses. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Bioxytran, Inc. a Nevada Corporation and its wholly owned subsidiary, Bioxytran, Inc. of Delaware (collectively, the “Company”). All intercompany accounts have been eliminated upon consolidation.

GOING CONCERN AND MANAGEMENT'S

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	9 Months Ended
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	Sep. 30, 2020
Going Concern and Management's Liquidity Plans [Abstract]
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of September 30, 2020, the Company had cash of $633 and a negative working capital of $2,092,530. As of September 30, 2020, the Company has not yet generated any revenues, and has incurred cumulative net losses of $3,912,439. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of December 2020, and is pursuing alternative opportunities to funding. The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. The Company is supplementing its disclosure previously disclosed in the Company's annual report on Form 10-K for the year ended December 31, 2019 and its subsequent quarterly reports on Form 10-Q with the following disclosure: Potential Impact of the COVID-19 Pandemic in December 2019, a strain of novel coronavirus (now commonly known as COVID-19) was reported to have surfaced in Wuhan, China. COVID-19 has since spread rapidly throughout many countries, and, on March 12, 2020, the World Health Organization declared COVID-19 to be a pandemic. In an effort to contain and mitigate the spread of COVID-19, many countries, including the United States, Canada and China, have imposed unprecedented restrictions on travel, and there have been business closures and a substantial reduction in economic activity in countries that have had significant outbreaks of COVID-19. COVID-19 may have a future material impact on our results of operation with respect to product development and clinical trials. However, significant uncertainty remains as to the potential impact of the COVID-19 pandemic on our operations, and on the global economy as a whole. It is currently not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to prior levels. We do not yet know the full extent of any impact on our business or our operations, however, we will continue to monitor the COVID-19 situation closely, and we intend to follow health and safety guidelines as they evolve. Accordingly, the accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

ACCOUNTS PAYABLES AND ACCRUED E

ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2020
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 3 – ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES On September 30, 2020, there was $259,135 in accounts payable to related parties in the form of payroll and accrued expenses. On December 31, 2019 there was $96,000 in accounts payable to related parties. The following table represents the major components of accounts payables and accrued expenses and other current liabilities at September 30, 2020 and December 31, 2019: September 30, 2020 December 31, 2019 Accounts payable related party (1) $ 259,135 $ 96,000 Professional fees 45,261 42,963 Interest 175,543 14,374 Payroll taxes — 7,344 Other accounts payable 253 7,251 ASC 480 debt premium — 24,121 Loan payable (2) 8,115 — Convertible notes payable 1,604,856 826,862 Total $ 2,093,163 $ 1,018,915 (1) $108,575 to each the CFO and the CEO for 17 months of salary and $41,985 to the Executive VP for 5 months of salary and advanced expenses for the period ending September 30 2020, while for the period ending December 31, 2019 there was $48,000 to each the CFO and the CEO for 8 months of salary. (2) A non-interest loan of $8,115 was given by a potential investor.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
CONVERTIBLE NOTES PAYABLE	Sep. 30, 2020
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 4 – CONVERTIBLE NOTES PAYABLE As long as the following convertible notes remain outstanding, the Company is restricted from incurring any indebtedness or liens, except as permitted (as defined), and cannot amend its charter in any matter that materially effects rights of noteholders, repay or repurchase more than de minimis number of shares of common stock other than conversion or warrant shares, repay or repurchase all or any portion of any indebtedness, or pay cash dividends. Auctus Note #1 On October 24, 2019 (the “Date of Issuance”) the Company issued a convertible promissory note (the “Auctus Note #1”) with a face value of $250,000, maturing on October 23, 2020, and a stated interest of 8% to a third-party investor. The Auctus Note #1 is convertible into common stock of the Company, par value $.001 per share (the “Common Stock”) at any time after the earlier of: (i) 180 days from the date of the Auctus Note #1, or (ii) upon effective date of a registration statement. The conversion price of the Auctus Note #1 is equal to the lesser of : (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #1 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Auctus Note #1 was funded on October 29, 2019, when the Company received proceeds of $222,205, after disbursements for the lender’s transaction costs, fees and expenses which in aggregate resulted in a total discount of $27,795 to be amortized to interest expense over the life of the Auctus Note #1. Additionally, the variable conversion rate component requires that the Auctus Note #1 be valued at its stock redemption value (i.e., “if-converted” value) pursuant to ASC 480, Distinguishing Liabilities from Equity Along with the Auctus Note #1, on the Date of Issuance the Company issued 208,333 Common Stock Purchase Warrants (the “Warrants”), exercisable immediately at a fixed exercise price of $0.60 with an expiration date of October 23, 2023. The Company has determined that the Warrants are exempt from derivative accounting and were valued at $101,937 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.49 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 251% and (5) risk free interest rate of 2.51%. The note proceeds of $250,000 were then allocated between the fair value of the Auctus Note #1 ($250,000) and the Warrants ($101,937), resulting in a debt discount of $72,412. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. Upon cashless conversion on March 12, 2020 an additional 166,667 warrants were issued for a market value of $66,363. The Auctus Note #1 was paid off on October 24, 2019, and the warrants were exercised on March 12,2020 Auctus Note #2 On February 25, 2019, the Company entered into a $250,000 Senior Secured Promissory Note (“the Auctus Note #2”), dated February 25, 2019 at an interest rate of 8% per annum, maturing on February 24, 2020 (the “Maturity Date”). Issuance fees totaling $27,750 were recorded as a debt discount, resulting in net proceeds of $222,250. The Auctus Note #2 is convertible into common stock of the Company, par value $.001 per share (the “Common Stock”) at any time after the earlier of: (i) 180 days from the date of the Auctus Note #2 or (ii) upon effective date of a new registration statement. The conversion price of the Auctus Note #2 is equal to the lesser of : (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #2 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Company may prepay the Auctus Note #2 at any time at a rate of 120% of outstanding principal and interest during the first 90 days it is outstanding and 130% of outstanding principal and interest for the next 90 days thereafter. Thereafter the prepayment amount increases 5% for each thirty-day period until 270 days from the issue date at which time it is fixed at 150% of the outstanding principal and interest on the Auctus Note #2. Additionally, the variable conversion rate component requires that the Auctus Note #2 be valued at its stock redemption value (i.e., “if-converted” value) pursuant to ASC 480, Distinguishing Liabilities from Equity, with the excess over the undiscounted face value being deemed a premium to be added to the principal balance and accreted to additional paid-in capital over the life of the Auctus Note #2. As such, the Company recorded a premium of $82,500 as a reduction to additional paid-in capital based on a discounted “if-converted” rate of $0.20 per share (lowest trading price during the 20 days preceding the note’s issuance), which computed to 1,250,000 shares of ‘if-converted’ common stock with a redemption value of $332,500 due to $0.266 per share fair market value of the Company’s stock on the Auctus Note #2’s date of issuance. Debt discount amortization is recorded as interest expense, while debt premium accretion is recorded as an increase to additional paid-in capital. For the nine months ending at September 30, 2020, the Company amortized $4,647 debt discount to operations as interest expense, and accreted $24,121 of premium to additional paid-in capital. Along with the the Auctus Note #2, on the Date of Issuance the Company issued 208,333 Common Stock Purchase Warrants (the “Warrants”), exercisable immediately at a fixed exercise price of $0.60 with an expiration date of February 24, 2024. The Company has determined that the Warrants are exempt from derivative accounting and were valued at $55,417 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.27 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 323% and (5) risk free interest rate of 2.56%. The Auctus Note #2 proceeds of $250,000 were then allocated between the fair value of the Auctus Note #2 ($250,000) and the Warrants ($55,417), resulting in a debt discount of $45,361. As the warrants are exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. Upon cashless conversion on March 12, 2020 an additional 166,667 warrants were issued for a market value of $66,364. The Auctus Note #2 was paid off on February 20, 2020, and the warrants were exercised on March 12,2020. Current notes convertible In the period January 1 to March 18, 2020 the Company entered into five contracts totaling $356,100 Senior Secured Promissory Note (“the Notes”), at an interest rate of 4-8% per annum, maturing in one year from issuance (the “Maturity Date”). Issuance fees totaling $50,100 were recorded as a debt discount, resulting in net proceeds of $306,000. The Notes are convertible into common stock of the Company, par value $.001 per share (the “Common Stock”) at any time after the earlier of: (i) 180 days from the date of the Notes or (ii) upon effective date of a new registration statement. The conversion price of the Notes is equal to the lesser of : (i) the lowest trading price for the twenty-day period prior to the date of the Notes or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Company may prepay the Notes at any time at a rate of 120% of outstanding principal and interest during the first 90 days it is outstanding and 130% of outstanding principal and interest for the next 90 days thereafter. Thereafter the prepayment amount increases 5% for each thirty-day period until 270 days from the issue date at which time it is fixed at 150% of the outstanding principal and interest on the Notes. The Company also issued five-year warrants with cashless exercise provisions to purchase shares of Common Stock of the Company at an exercise price of $2.00 per share with cashless exercise provisions. For the nine months ending at September 30, 2020, the Company issued 72,000 warrants, resulting in an amortized debt discount of $12,711. There were no warrants issued in the three-month period ending at September 30, 2020. Default on notes convertible On April 16, 2020, SEC ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading of BIXT is suspended for the period April 16 through April 29, 2020. As a result of the SEC ordered suspension the Company defaulted on outstanding Convertible Notes; resulting in an increase of the interest to 21% and the principal to increase to 168% of principal loan amount. The convertible debt increased by $666,456 to $1,604,856 while the interest accrual increased to approximately $28,563/month, amounting to $175,543 at date of September 30, 2020. At the default date, April 16, 2020, remaining debt discount of $76,265 was amortized to interest expense and the remaining debt premium of $856,560 was accredited to additional paid-in capital. A summary of the outstanding notes at September 30, 2020, are as follows: Debtor Date of Issuance Default Date Principal Amount Default Penalty Default Interest Warrants Issued Term Exercise Price Amortization of Warrants Accrued Interest GS Capital 10/30/2019 4/16/2020 $ 125,000 $ 65,808 24 % 50,000 5 $ 2.00 $ 23,867 $ 23,158 Power Up #1 10/24/2019 4/16/2020 106,000 114,224 22 % — — — — 26,279 Peak One 10/23/2019 4/16/2020 120,000 36,000 18 % 50,000 5 2.00 21,606 12,848 Tangiers 10/23/2019 4/16/2020 106,300 48.261 18 % 50,000 5 2.00 21,116 16,830 FirstFire 11/20/2019 4/16/2020 125,000 65,541 24 % 50,000 5 2.00 17,979 22,950 Power Up #2 12/30/2019 4/16/2020 54,600 57,185 22 % — — — — 12,544 EMA Financial 01/10/2020 4/16/2020 125,000 127,658 24 % 50,000 5 2.00 5,948 29,073 Crown Bridge 02/20/2020 4/16/2020 55,000 28,015 15 % 22,000 5 2.00 6,763 6,041 Power Up #3 02/19/2020 4/16/2020 56,600 58,039 22 % — — — — 12,259 Power Up #4 03/18/2020 4/16/2020 64,900 65,725 22 % — — — — 13,651 $ 938,400 $ 666,456 272,000 $ 97,279 $ 175,543 Convertible notes payable consists of the following at September 30, 2020 and December 31, 2019: September 30, December 31, Principal balance $ 938,400 $ 886,900 Default penalty 666,456 — Unamortized debt discount — (60,038 ) Unamortized debt premium — 24,121 Outstanding, net of debt discount and premium $ 1,604,856 $ 850,983

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
STOCKHOLDERS' EQUITY	Sep. 30, 2020
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 5 – STOCKHOLDERS’ EQUITY At a Board of Director’s Meeting on July 30, 2019, the Company authorized a reverse stock split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective on August 13, 2019, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital. As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock. The reverse split has been retroactively applied to all periods presented. Preferred stock As of September 30, 2020, and December 31, 2019, no preferred shares have been designated or issued. Common stock On May 30, 2019, 25,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #1 at $0.20 per share for a total of $5,000. On July 18, 2019, 25,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #1 at $0.20 per share for a total of $5,000. On August 20, 2019, 20,000 shares of common stock were sold and issued from the active S-1 at $1 per share for a total of $20,000. On August 22, 2019, 25,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #1 at $0.20 per share for a total of $5,000. On January 3, 2020, 100,000 shares of common stock were issued as a result of conversion of accrued interest and principal on the Auctus Note #2 for a total of $12,000. On February 18, 2020, 250,000 shares of common stock were issued as a result of conversion of accrued interest and principal on the Auctus Note #2 for a total of $22,132. On March 12, 2020, 750,000 of common stock were issued in exchange for 416,666 warrants with cashless exercise, originating from Auctus Notes #1 and #2. For the nine months ending September 30, 2020, 9,609,000 shares were awarded with an average cost per share of $0.01, under the 2010 Stock Plan for a total value of $161,667. The Company recorded $34,600 in stock-based compensation for 108,000 issued shares in the nine months ended September 30, 2019. For details, see Shares Awarded and Issued under Note 6. At September 30, 2020, the Company had 97,184,673 shares of common stock issued and outstanding. At December 31, 2019 there were 86,475,673 shares of common stock issued and outstanding. Common Stock Warrants During the nine months ending September 30, 2020 the Company awarded 405,334 warrants, valued at $145,438, and 750,000 shares of common stock were issued in a cashless exercise. During the nine months ending September 30, 2019 the Company awarded 208,333 warrants valued at $45,361. The following table summarizes the Company’s common stock warrant activity for the nine months ended September 30, 2020 and September 30, 2019: Weighted Average Weighted- Average Remaining Warrants Exercise Price Expected Term Outstanding as of January 1, 2019 208,333 $ 0.60 4.6 Granted 208,333 0.60 4.9 Exercised — — — Forfeited/Canceled — — — Outstanding as of September 30, 2019 416,666 $ 0.60 4.7 Outstanding as of January 1, 2020 616,666 $ 1.05 4.0 Granted 405,334 0.36 0.9 Exercised (750,000 ) — — Forfeited/Canceled — — — Outstanding as of September 30, 2020 272,000 $ 2.00 4.2 During the nine months ending September 30, 2020, the Company awarded 144,000 options under the 2010 Stock Plan, with a fair market value of $12,533. The Company recorded a compensation expense of $228,058 for 293,000 options issued during the nine months ended September 30, 2019.

STOCK OPTION PLAN AND STOCK-BAS

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION	9 Months Ended
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION	NOTE 6 – STOCK OPTION PLAN AND STOCK-BASED COMPENSATION During the year ended December 31, 2010, the Company adopted a stock option plan entitled “The 2010 Stock Plan” (2010 Plan) under which the Company may grant Options to Purchase Stock, Stock Awards or Stock Appreciation Rights up to 15% of common stock, automatically adjusted on January 1 each year. As of January 1, 2019, there were no outstanding awards under the 2010 Plan. As of January 1, 2020, there were 341,000 outstanding stock options with a fair market value of $257,143 and 1,127,000 shares issued with a fair market value of $864,551 at the time of award. Under the terms of the stock plans, the Board of Directors shall specify the exercise price and vesting period of each stock option on the grant date. Vesting of the options is typically immediate and the options typically expire in five years. Stock Awards may be directly issued under the Plan (without any intervening options). Stock Awards may be issued which are fully and immediately vested upon issuance. Shares Awarded and Issued: On January 1, 2020 the Company granted 250,000 shares with a fair market value of $0.285/share at the time of award, to a consultant for assistance with the Companies PR work, for a total of $71,250. On January 31, 2020 the Company granted two subcontractors a total of 200,000 shares with a fair market value of $0.14/share at the time of award, as compensation for their work with the Company’s marketing efforts, for a total of $28,000. On March 18, 2020 the Company granted 200,000 shares with a fair market value of $0.245/share at the time of award, to a consultant for assistance with the Companies PR work, for a total of $49,000. On February 21, 2020 the Company granted 3,000 shares with a fair market value of $0.439/share to three members of the Audit Committee as compensation for their contribution in the Audit Committee, for a total of $1,317. On March 25, 2020, the Company granted 3,000 shares with a fair market value of $0.31/share to three members of the Company Board as compensation for their contribution in the Company’s Board of Directors, for a total of $930. On May 1, 2020 the Company appointed Mr. Mike Sheikh as EVP of Business Development. Mr. Sheikh was issued 8,800,000 shares with a fair market value of $0.001/share to be equally vested over a period of 3 years, but fully vested upon a change of control. The shares total fair value at the time of the award was $8,800. On July 1, 2020, the Company granted 3,000 shares with a fair market value of $0.19/share to three members of the Company Board as compensation for their contribution in the Board and Committee contribution during the previous quarter, for a total of $570. On August 3, 2020, the Company granted a total of 100,000 shares, to two Medical Consultants for their efforts in validating the Company’s science and potential clinical pathways. The shares total fair value at the time of award was $300. On September 17, 2020, the Company granted a total of 50,000 shares, to a Medical Consultants for his efforts in validating the Company’s science and potential clinical pathways. The shares total fair value at the time of award was $1,500. Number of Shares Fair Value per Share Weighted Average Market Value per Share Shares Issued as of December 31, 2019 1,127,000 $ 0.27 - 1.49 $ 0.77 Shares Issued 9,609,000 0.001 – 0.44 0.02 Shares Issued as of September 30, 2020 10,736,000 $ 0.001 - 1.49 $ 0.10 Stock options granted and vested: On January 1, 2020 the Company granted 3,000 three-year options at an exercise price of $0.31 to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of award was $603. On February 1, 2020 the Company granted 45,000 three-year options at an exercise price of $0.15 to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of award was $4,401. On April 1, 2020 the Company granted 3,000 three-year options at an exercise price of $0.32 to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $646. On May 1, 2020 the Company granted 45,000 three-year options at an exercise price of $0.001 to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $45. On July 1, 2020 the Company granted 3,000 three-year options at an exercise price of $0.18/share to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $538. On August 1, 2020 the Company granted 45,000 three-year options at an exercise price of $0.14/share to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $6,300. The fair value of stock options granted and revaluation of non-employee consultant options for the nine months ended September 30, 2020 was calculated with the following assumptions: 2020 Risk-free interest rate 0.36 – 1.69 % Expected dividend yield 0 % Volatility factor (weekly) 340.42 % Expected life of option 3 years For the nine months ended September 30, 2020, the Company recorded compensation expense of $12,533 in connection with awarded stock options. The Company recorded a compensation expense of $228,058 for 293,000 options issued during the nine months ended September 30, 2019. As at September 30, 2020, there was no unrecognized compensation expense related to non-vested stock option awards. The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2020: Number of Options Exercise Price per Share Weighted Average Exercise Price per Share Outstanding as of December 31, 2019 341,000 $ 0.61 - 1.21 $ 0.96 Granted 144,000 0.001 - 0.31 0.11 Exercised — — — Options forfeited/cancelled — — — Outstanding as of September 30, 2020 485,000 $ 0.001 - 1.21 $ 0.71 The following table summarizes information about stock options that are vested or expected to vest at September 30, 2020: Options Outstanding Exercisable Options Exercise Price Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value $ 0.001 45,000 $ 0.001 2.58 $ — 45,000 $ 0.001 2.58 $ — 0.15 90,000 0.15 2.33 — 90,000 0.15 2.33 — 0.20 3,000 0.20 2.75 — 3,000 0.20 2.75 — 0.31 3,000 0.31 2.25 — 3,000 0.31 2.25 — 0.32 3,000 0.32 2.50 — 3,000 0.32 2.50 — 0.73 3,000 0.73 2.00 — 3,000 0.73 2.00 — 0.61 45,000 0.61 2.08 — 45,000 0.61 2.08 — 0.95 200,000 0.95 1.95 — 200,000 0.95 1.95 — 1.09 3,000 1.09 1.75 — 3,000 1.09 1.75 — 1.10 45,000 1.10 1.83 — 45,000 1.10 1.83 — 1.21 45,000 1.21 1.58 — 45,000 1.21 1.58 — $ 0.001-1.21 485,000 $ 0.71 2.10 $ — 485,000 $ 0.71 2.10 $ — The following table sets forth the status of the Company’s non-vested stock options as of September 30, 2020 and December 31, 2019: Number of Options Weighted- Average Grant-Date Fair Value Non-vested as of December 31, 2019 — $ — Granted 144,000 0.11 Forfeited — — Vested (144,000 ) 0.11 Non-vested as of September 30, 2020 — $ — The weighted-average remaining estimated life for options exercisable at September 30, 2020 is 2.10 years. The aggregate intrinsic value for fully vested, exercisable options was $0 at September 30, 2020 and 2019. The aggregate intrinsic value of options exercised for the nine months ended at September 30, 2020 and 2019 was $0 as no options were exercised. At September 30, 2020 the Company has 1,530,151 options or stock awards available for grant under the 2010 Plan.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES Employment contracts The Company’s executive officers have entered employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The employment agreements do not provide for the payment of any compensation to our executive officers but provide for the payment of $100,000 in severance upon termination of employment without cause and make no provisions for any payment upon a change of control. Litigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable. On June 5, 2020 the Supreme Court of the State of New York, County of Nassau, issued a commencement of Action based on behalf of Power Up Lending Group, Ltd (“Power Up” or the “Claimant”). The Claimant request that due to the default of their note requesting a judgment for an amount of not less than $420,750. Among other claims Power Up asserts that the Company willfully failed to maintain the trading status, and manipulated its stock in its efforts to defraud the public and its investors by making false press statements and the like. The Company is denying any wrong-doing. However, the full requested amount has been included in the default calculation of the convertible debt.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS Stock options and shares granted under the 2010 Stock Plan: On October 1, 2020, the Company granted 3,000 shares with a fair market value of $0.02/share to three members of the Company Board as compensation for their contribution in the Board and Committee contribution during the previous quarter, for a total of $60. On October 1, 2020 the Company granted 3,000 three-year options at an exercise price of $0.05/share to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $135. On November 1, 2020 the Company granted 45,000 three-year options at an exercise price of $0.18/ 5,792 The Company’s management has evaluated events occurring after September 30, 2020 through the date the financial statements were issued and did not identify any further subsequent events requiring disclosure.

ACCOUNTS PAYABLES AND ACCRUED_2

ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2020
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of accounts payables and accrued expenses and other current liabilities	The following table represents the major components of accounts payables and accrued expenses and other current liabilities at September 30, 2020 and December 31, 2019: September 30, 2020 December 31, 2019 Accounts payable related party (1) $ 259,135 $ 96,000 Professional fees 45,261 42,963 Interest 175,543 14,374 Payroll taxes — 7,344 Other accounts payable 253 7,251 ASC 480 debt premium — 24,121 Loan payable (2) 8,115 — Convertible notes payable 1,604,856 826,862 Total $ 2,093,163 $ 1,018,915 (1) $108,575 to each the CFO and the CEO for 17 months of salary and $41,985 to the Executive VP for 5 months of salary and advanced expenses for the period ending September 30 2020, while for the period ending December 31, 2019 there was $48,000 to each the CFO and the CEO for 8 months of salary. (2) A non-interest loan of $8,115 was given by a potential investor.

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
CONVERTIBLE NOTES PAYABLE (Tables)	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of outstanding notes	A summary of the outstanding notes at September 30, 2020, are as follows: Debtor Date of Issuance Default Date Principal Amount Default Penalty Default Interest Warrants Issued Term Exercise Price Amortization of Warrants Accrued Interest GS Capital 10/30/2019 4/16/2020 $ 125,000 $ 65,808 24 % 50,000 5 $ 2.00 $ 23,867 $ 23,158 Power Up #1 10/24/2019 4/16/2020 106,000 114,224 22 % — — — — 26,279 Peak One 10/23/2019 4/16/2020 120,000 36,000 18 % 50,000 5 2.00 21,606 12,848 Tangiers 10/23/2019 4/16/2020 106,300 48.261 18 % 50,000 5 2.00 21,116 16,830 FirstFire 11/20/2019 4/16/2020 125,000 65,541 24 % 50,000 5 2.00 17,979 22,950 Power Up #2 12/30/2019 4/16/2020 54,600 57,185 22 % — — — — 12,544 EMA Financial 01/10/2020 4/16/2020 125,000 127,658 24 % 50,000 5 2.00 5,948 29,073 Crown Bridge 02/20/2020 4/16/2020 55,000 28,015 15 % 22,000 5 2.00 6,763 6,041 Power Up #3 02/19/2020 4/16/2020 56,600 58,039 22 % — — — — 12,259 Power Up #4 03/18/2020 4/16/2020 64,900 65,725 22 % — — — — 13,651 $ 938,400 $ 666,456 272,000 $ 97,279 $ 175,543
Schedule of convertible notes payable	Convertible notes payable consists of the following at September 30, 2020 and December 31, 2019: September 30, December 31, Principal balance $ 938,400 $ 886,900 Default penalty 666,456 — Unamortized debt discount — (60,038 ) Unamortized debt premium — 24,121 Outstanding, net of debt discount and premium $ 1,604,856 $ 850,983

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
STOCKHOLDERS' EQUITY (Tables)	Sep. 30, 2020
Equity [Abstract]
Schedule of company's common stock warrants activity	The following table summarizes the Company’s common stock warrant activity for the nine months ended September 30, 2020 and September 30, 2019: Weighted Average Weighted- Average Remaining Warrants Exercise Price Expected Term Outstanding as of January 1, 2019 208,333 $ 0.60 4.6 Granted 208,333 0.60 4.9 Exercised — — — Forfeited/Canceled — — — Outstanding as of September 30, 2019 416,666 $ 0.60 4.7 Outstanding as of January 1, 2020 616,666 $ 1.05 4.0 Granted 405,334 0.36 0.9 Exercised (750,000 ) — — Forfeited/Canceled — — — Outstanding as of September 30, 2020 272,000 $ 2.00 4.2

STOCK OPTION PLAN AND STOCK-B_2

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Tables)	9 Months Ended
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Tables)	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Summary of fair value of stock awards granted	On September 17, 2020, the Company granted a total of 50,000 shares, to a Medical Consultants for his efforts in validating the Company’s science and potential clinical pathways. The shares total fair value at the time of award was $1,500. Number of Shares Fair Value per Share Weighted Average Market Value per Share Shares Issued as of December 31, 2019 1,127,000 $ 0.27 - 1.49 $ 0.77 Shares Issued 9,609,000 0.001 – 0.44 0.02 Shares Issued as of September 30, 2020 10,736,000 $ 0.001 - 1.49 $ 0.10
Summary of stock options granted valuation assumptions	The fair value of stock options granted and revaluation of non-employee consultant options for the nine months ended September 30, 2020 was calculated with the following assumptions: 2020 Risk-free interest rate 0.36 – 1.69 % Expected dividend yield 0 % Volatility factor (weekly) 340.42 % Expected life of option 3 years
Summary of stock option activity	The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2020: Number of Options Exercise Price per Share Weighted Average Exercise Price per Share Outstanding as of December 31, 2019 341,000 $ 0.61 - 1.21 $ 0.96 Granted 144,000 0.001 - 0.31 0.11 Exercised — — — Options forfeited/cancelled — — — Outstanding as of September 30, 2020 485,000 $ 0.001 - 1.21 $ 0.71
Summary of stock options vested or expected to vest	The following table summarizes information about stock options that are vested or expected to vest at September 30, 2020: Options Outstanding Exercisable Options Exercise Price Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value $ 0.001 45,000 $ 0.001 2.58 $ — 45,000 $ 0.001 2.58 $ — 0.15 90,000 0.15 2.33 — 90,000 0.15 2.33 — 0.20 3,000 0.20 2.75 — 3,000 0.20 2.75 — 0.31 3,000 0.31 2.25 — 3,000 0.31 2.25 — 0.32 3,000 0.32 2.50 — 3,000 0.32 2.50 — 0.73 3,000 0.73 2.00 — 3,000 0.73 2.00 — 0.61 45,000 0.61 2.08 — 45,000 0.61 2.08 — 0.95 200,000 0.95 1.95 — 200,000 0.95 1.95 — 1.09 3,000 1.09 1.75 — 3,000 1.09 1.75 — 1.10 45,000 1.10 1.83 — 45,000 1.10 1.83 — 1.21 45,000 1.21 1.58 — 45,000 1.21 1.58 — $ 0.001-1.21 485,000 $ 0.71 2.10 $ — 485,000 $ 0.71 2.10 $ —
Summary of non-vested stock options	The following table sets forth the status of the Company’s non-vested stock options as of September 30, 2020 and December 31, 2019: Number of Options Weighted- Average Grant-Date Fair Value Non-vested as of December 31, 2019 — $ — Granted 144,000 0.11 Forfeited — — Vested (144,000 ) 0.11 Non-vested as of September 30, 2020 — $ —

BACKGROUND AND ORGANIZATION (De

BACKGROUND AND ORGANIZATION (Details Narrative) - $ / shares	Sep. 30, 2020	Dec. 31, 2019	Sep. 21, 2019	Oct. 05, 2017
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Delaware [Member]
Common stock, par value			$ 0.001	$ 0.0001
Common stock, shares authorized			300,000,000	95,000,000
Preferred stock, par value			$ 0.001	$ 0.0001
Preferred stock, shares authorized			50,000,000	5,000,000

GOING CONCERN AND MANAGEMENT'_2

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Going Concern and Management's Liquidity Plans (Textual)
Cash	$ 633	$ 169,628	$ 33,226	$ 36,411
Negative working capital	2,092,530
Cumulative net losses	$ 3,912,439	$ 2,241,305

ACCOUNTS PAYABLES AND ACCRUED_3

ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)		Sep. 30, 2020	Dec. 31, 2019
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
Accounts payable related party	[1]	$ 259,135	$ 96,000
Professional fees		45,261	42,963
Interest		175,543	14,374
Payroll taxes			7,344
Other accounts payable		253	7,251
ASC 480 debt premium			24,121
Loan payable	[2]	8,115
Convertible notes payable		1,604,856	826,862
Total		$ 2,093,163	$ 1,018,915

[1]	$108,575 to each the CFO and the CEO for 17 months of salary and $41,985 to the Executive VP for 5 months of salary and advanced expenses for the period ending September 30 2020, while for the period ending December 31, 2019 there was $48,000 to each the CFO and the CEO for 8 months of salary.
[2]	A non-interest loan of $8,115 was given by a potential investor.

ACCOUNTS PAYABLES AND ACCRUED_4

ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details Narrative) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2020	Dec. 31, 2019
Accrued expenses in accounts payables to related parties		$ 259,135	$ 96,000
Non-interest loan	[1]	8,115
CFO [Member]
Accrued salary expenses		$ 108,575	$ 48,000
Duration of accrued salary paid		17 months	8 months
CEO [Member]
Accrued salary expenses		$ 108,575	$ 48,000
Duration of accrued salary paid		17 months	8 months
Executive Vice President [Member]
Accrued salary expenses		$ 41,985
Duration of accrued salary paid		5 months

[1]	A non-interest loan of $8,115 was given by a potential investor.

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details)	9 Months Ended
CONVERTIBLE NOTES PAYABLE (Details)	Sep. 30, 2020USD ($)$ / sharesshares
Principal Amount	$ 938,400
Default Penalty	$ 666,456
Warrants Issued \| shares	272,000
Amortization of Warrants	$ 97,279
Accrued Interest	$ 175,543
GS Capital [Member]
Debtor	GS Capital
Date of Issuance	Oct. 30, 2019
Maturity Date	Apr. 16, 2020
Principal Amount	$ 125,000
Default Penalty	$ 65,808
Default Interest	24.00%
Warrants Issued \| shares	50,000
Term	5 years
Exercise Price \| $ / shares	$ 2
Amortization of Warrants	$ 23,867
Accrued Interest	$ 23,158
Power Up #1 [Member]
Debtor	Power Up #1
Date of Issuance	Oct. 24, 2019
Maturity Date	Apr. 16, 2020
Principal Amount	$ 106,000
Default Penalty	$ 114,224
Default Interest	22.00%
Warrants Issued \| shares
Exercise Price \| $ / shares
Amortization of Warrants
Accrued Interest	$ 26,279
Peak One [Member]
Debtor	Peak One
Date of Issuance	Oct. 23, 2019
Maturity Date	Apr. 16, 2020
Principal Amount	$ 120,000
Default Penalty	$ 36,000
Default Interest	18.00%
Warrants Issued \| shares	50,000
Term	5 years
Exercise Price \| $ / shares	$ 2
Amortization of Warrants	$ 21,606
Accrued Interest	$ 12,848
Tangiers [Member]
Debtor	Tangiers
Date of Issuance	Oct. 23, 2019
Maturity Date	Apr. 16, 2020
Principal Amount	$ 106,300
Default Penalty	$ 48,261
Default Interest	18.00%
Warrants Issued \| shares	50,000
Term	5 years
Exercise Price \| $ / shares	$ 2
Amortization of Warrants	$ 21,116
Accrued Interest	$ 16,830
FirstFire [Member]
Debtor	FirstFire
Date of Issuance	Nov. 20, 2019
Maturity Date	Apr. 16, 2020
Principal Amount	$ 125,000
Default Penalty	$ 65,541
Default Interest	24.00%
Warrants Issued \| shares	50,000
Term	5 years
Exercise Price \| $ / shares	$ 2
Amortization of Warrants	$ 17,979
Accrued Interest	$ 22,950
Power Up #2 [Member]
Debtor	Power Up #2
Date of Issuance	Dec. 30, 2019
Maturity Date	Apr. 16, 2020
Principal Amount	$ 54,600
Default Penalty	$ 57,185
Default Interest	22.00%
Warrants Issued \| shares
Exercise Price \| $ / shares
Amortization of Warrants
Accrued Interest	$ 12,544
EMA Financial [Member]
Debtor	EMA Financial
Date of Issuance	Jan. 10, 2020
Maturity Date	Apr. 16, 2020
Principal Amount	$ 125,000
Default Penalty	$ 127,658
Default Interest	24.00%
Warrants Issued \| shares	50,000
Term	5 years
Exercise Price \| $ / shares	$ 2
Amortization of Warrants	$ 5,948
Accrued Interest	$ 29,073
Crown Bridge [Member]
Debtor	Crown Bridge
Date of Issuance	Feb. 20, 2020
Maturity Date	Apr. 16, 2020
Principal Amount	$ 55,000
Default Penalty	$ 28,015
Default Interest	15.00%
Warrants Issued \| shares	22,000
Term	5 years
Exercise Price \| $ / shares	$ 2
Amortization of Warrants	$ 6,763
Accrued Interest	$ 6,041
Power Up #3 [Member]
Debtor	Power Up #3
Date of Issuance	Feb. 19, 2020
Maturity Date	Apr. 16, 2020
Principal Amount	$ 56,600
Default Penalty	$ 58,039
Default Interest	22.00%
Warrants Issued \| shares
Exercise Price \| $ / shares
Amortization of Warrants
Accrued Interest	$ 12,259
Power Up #4 [Member]
Debtor	Power Up #4
Date of Issuance	Mar. 18, 2020
Maturity Date	Apr. 16, 2020
Principal Amount	$ 64,900
Default Penalty	$ 65,725
Default Interest	22.00%
Warrants Issued \| shares
Exercise Price \| $ / shares
Amortization of Warrants
Accrued Interest	$ 13,651

CONVERTIBLE NOTES PAYABLE (De_2

CONVERTIBLE NOTES PAYABLE (Details 1) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Default penalty	$ 666,456
Unamortized debt premium		$ 24,121
Convertible Notes Payable [Member]
Principal balance	938,400	886,900
Default penalty	666,456
Unamortized debt discount		(60,038)
Unamortized debt premium		24,121
Outstanding, net of debt discount and premium	$ 1,604,856	$ 850,983

CONVERTIBLE NOTES PAYABLE (De_3

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)

Mar. 12, 2020

Feb. 25, 2020

Feb. 18, 2020

Jan. 03, 2020

Oct. 24, 2019

Aug. 22, 2019

May 30, 2019

Jul. 18, 2019

Sep. 30, 2020

Sep. 30, 2019

Sep. 30, 2020

Sep. 30, 2019

Dec. 31, 2019

Oct. 23, 2019

Common stock per share

$ 0.001

Principal balance

$ 938,400

Interest expense

86,593

$ 10,002

919,677

$ 26,891

Additional paid-in capital

1,722,724

$ 1,355,542

Additional Warrant issued

$ 166,667

Fair value amount

$ 66,364

Amortized debt discount

$ 97,279

Auctus Note 1 and 2 [Member]

Common stock purchase warrants issued

750,000

Auctus Note 2 [Member]

Common stock per share

$ 0.60

Expiration date

Feb. 24,
2024

Convertible note, description

The variable conversion rate component requires that the Auctus Note #2 be valued at its stock redemption value (i.e., "if-converted" value) pursuant to ASC 480, Distinguishing Liabilities from Equity, with the excess over the undiscounted face value being deemed a premium to be added to the principal balance and accreted to additional paid-in capital over the life of the Auctus Note #2. As such, the Company recorded a premium of $82,500 as a reduction to additional paid-in capital based on a discounted "if-converted" rate of $0.20 per share (lowest trading price during the 20 days preceding the note’s issuance), which computed to 1,250,000 shares of "if-converted" common stock with a redemption value of $332,500 due to $0.266 per share fair market value of the Company’s stock on the Auctus Note #2’s date of issuance. Debt discount amortization is recorded as interest expense, while debt premium accretion is recorded as an increase to additional paid-in capital.

Determined warrants derivative, description

The Company has determined that the Warrants are exempt from derivative accounting and were valued at $55,417 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.27 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 323% and (5) risk free interest rate of 2.56%. The Auctus Note #2 proceeds of $250,000 were then allocated between the fair value of the Auctus Note #2 ($250,000) and the Warrants ($55,417), resulting in a debt discount of $45,361. As the warrants are exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. Upon cashless conversion on March 12, 2020 an additional 166,667 warrants were issued for a market value of $66,364.

Common stock purchase warrants issued

208,333

250,000

100,000

72,000

Interest expense

$ 4,647

Amortized debt discount

12,711

Premium to additional paid-in capital

$ 24,121

24,121

Auctus Note 2 [Member] | Secured Promissory Note [Member]

Convertible notes issued

$ 27,750

Common stock per share

$ 0.001

Expiration date

Feb. 24,
2020

Convertible note, description

(i) 180 days from the date of the Auctus Note #2 or (ii) upon effective date of a new registration statement. The conversion price of the Auctus Note #2 is equal to the lesser of : (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #2 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Company may prepay the Auctus Note #2 at any time at a rate of 120% of outstanding principal and interest during the first 90 days it is outstanding and 130% of outstanding principal and interest for the next 90 days thereafter. Thereafter the prepayment amount increases 5% for each thirty-day period until 270 days from the issue date at which time it is fixed at 150% of the outstanding principal and interest on the Auctus Note #2.

Principal balance

$ 250,000

Stated interest

8.00%

Net proceeds

$ 222,250

Notes Not Yet Convertible [Member] | Secured Promissory Note [Member]

Debt discount

$ 73,300

Common stock per share

$ 0.001

Principal balance

$ 636,800

Auctus Note 1 [Member]

Common stock per share

$ 0.001

Expiration date

Oct. 23,
2020

Convertible note, description

(i) 180 days from the date of the Auctus Note #1, or (ii) upon effective date of a registration statement. The conversion price of the Auctus Note #1 is equal to the lesser of : (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #1 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Auctus Note #1 was funded on October 29, 2019, when the Company received proceeds of $222,205, after disbursements for the lender's transaction costs, fees and expenses which in aggregate resulted in a total discount of $27,795 to be amortized to interest expense over the life of the Auctus Note #1.

Determined warrants derivative, description

The Company has determined that the Warrants are exempt from derivative accounting and were valued at $101,937 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.49 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 251% and (5) risk free interest rate of 2.51%. The note proceeds of $250,000 were then allocated between the fair value of the Auctus Note #1 ($250,000) and the Warrants ($101,937), resulting in a debt discount of $72,412.

Principal balance

$ 250,000

Stated interest

8.00%

Debt premium

$ 343,796

Common stock purchase warrants issued

208,333

25,000

Auctus Note 1 [Member] | Convertible Notes Payable [Member]

Common stock per share

$ 0.001

Expiration date

Oct. 23,
2023

Convertible note, description

"if-converted" rate of $0.21 per share (65% of the average of the three lowest trading prices during the 20 days preceding the note's issuance), which computed to 1,211,828 shares of "if-converted" common stock with a redemption value of $593,796 due to $0.49 per share fair market value of the Company’s stock on the Auctus Note #1's date of issuance. Debt discount amortization is recorded as interest expense, while debt premium amortization is recorded as an increase to additional paid-in capital.

Warrants exercise price

$ 0.60

Other Notes Currently Convertible [Member]

Debt premium

$ 937,007

Other Notes Currently Convertible [Member] | Secured Promissory Note [Member]

Debt discount

$ 37,100

Common stock per share

$ 0.001

Convertible note, description

(i) 180 days from the date of the Notes or (ii) upon effective date of a new registration statement. The conversion price of the Notes is equal to the lesser of : (i) the lowest trading price for the twenty-day period prior to the date of the Notes or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Company may prepay the Notes at any time at a rate of 120% of outstanding principal and interest during the first 90 days it is outstanding and 130% of outstanding principal and interest for the next 90 days thereafter. Thereafter the prepayment amount increases 5% for each thirty-day period until 270 days from the issue date at which time it is fixed at 150% of the outstanding principal and interest on the Notes.

Principal balance

$ 300,000

Net proceeds

$ 255,000

Interest expense

6,415

Auctus Note 2 [Member]

Interest expense

$ 175,543

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - $ / shares	9 Months Ended
STOCKHOLDERS' EQUITY (Details) - $ / shares	Sep. 30, 2020	Sep. 30, 2019
Number of shares, Exercised		293,000
Warrant [Member]
Number of shares, Outstanding, Beginning balance	616,666	208,333
Number of shares, Granted	405,334	208,333
Number of shares, Exercised	(750,000)
Number of shares, Forfeited/Canceled
Number of shares, Outstanding, Ending balance	272,000	416,666
Weighted Average Exercise Price, Outstanding as of beginning	$ 1.05	$ 0.60
Weighted-Average Exercise Price, granted	0.36	0.60
Weighted-Average Exercise Price, exercised
Weighted-Average Exercise Price, Forfeited/Cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	$ 2	$ 0.60
Weighted-Average Remaining Expected Term, Beginning balance	4 years	4 years 7 months 6 days
Weighted-Average Remaining Expected Term, Options granted	10 months 24 days	4 years 10 months 24 days
Weighted-Average Remaining Expected Term, Ending balance	4 years 2 months 12 days	4 years 8 months 12 days

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Mar. 12, 2020	Feb. 25, 2020	Feb. 18, 2020	Jan. 03, 2020	Oct. 24, 2019	Aug. 22, 2019	Aug. 20, 2019	May 30, 2019	Jul. 30, 2019	Jul. 18, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Class of Stock [Line Items]
Description of reverse stock split									The Company authorized a reverse stock split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective on August 13, 2019, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital. As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock. The reverse split has been retroactively applied to all periods presented.
Preferred stock, shares issued
Common stock, shares issued											97,184,673		86,475,673
Common stock, shares outstanding											97,184,673		86,475,673
Warrants as part of a convertible note agreement											272,000
Fair market value of warrant	$ 66,364
Stock based compensation, value											$ 34,600
Stock based compensation, issued											108,000
Compensation expense option												$ 228,058
compensation expense option share												293,000
Warrant [Member]
Class of Stock [Line Items]
Warrant											405,334	208,333
Warrant value											$ 145,438	$ 45,361
Warrants converted cashless exercise											750,000
compensation expense option share											(750,000)
2010 Stock Plan [Member]
Class of Stock [Line Items]
Conversion of accrued interest											$ 161,667
Shares issued for conversion of accrued interest, shares											9,609,000
Share price (in dollars per share)											$ 0.01
Awarded option											144,000
Fair market value of warrant											$ 12,533
Auctus Note 1 [Member]
Class of Stock [Line Items]
Conversion of accrued interest						$ 5,000		$ 5,000		$ 5,000
Shares issued for conversion of accrued interest, shares					208,333	25,000		25,000		25,000
Share price (in dollars per share)						$ 0.20		$ 0.20		$ 0.20
S-1 [Member]
Class of Stock [Line Items]
Conversion of accrued interest							$ 20,000
Shares issued for conversion of accrued interest, shares							20,000
Share price (in dollars per share)							$ 1
Auctus Note 2 [Member]
Class of Stock [Line Items]
Conversion of accrued interest			$ 22,132	$ 12,000
Shares issued for conversion of accrued interest, shares		208,333	250,000	100,000							72,000
Auctus Note 1 and 2 [Member]
Class of Stock [Line Items]
Shares issued for conversion of accrued interest, shares	750,000
Warrants as part of a convertible note agreement	416,666

STOCK OPTION PLAN AND STOCK-B_3

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details) - Stock Awards Plan [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Number of shares issued, December 31, 2019 \| shares	1,127,000
Number of shares, Shares Issued \| shares	9,609,000
Number of shares issued, September 30, 2020 \| shares	10,736,000
Weighted Average Market Value per share, December 31, 2019	$ 0.77
Weighted Average Market Value per Share, Shares issued	0.02
Weighted Average Market Value per Share, September 30, 2020	0.10
Minimum [Member]
Fair value per share of December 31, 2019	0.27
Fair value per share, Shares Issued	0.001
Fair Value per Share, September 30, 2020	0.001
Maximum [Member]
Fair value per share of December 31, 2019	1.49
Fair value per share, Shares Issued	0.44
Fair Value per Share, September 30, 2020	$ 1.49

STOCK OPTION PLAN AND STOCK-B_4

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details 1)	9 Months Ended
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details 1)	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Risk-free interest rate, Minimum	0.36%
Risk-free interest rate, Maximum	1.69%
Expected dividend yield	0.00%
Volatility factor (weekly)	340.42%
Expected life of option	3 years

STOCK OPTION PLAN AND STOCK-B_5

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details 2) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Exercised		293,000
Share-based Payment Arrangement, Option [Member]
Number of shares, Outstanding, Beginning balance	341,000
Number of shares, Granted	144,000
Exercised
Options forfeited/cancelled
Number of shares, Outstanding, Ending balance	485,000
Weighted Average Exercise Price, Outstanding as of beginning	$ 0.96
Weighted Average Exercise Price per Share, Granted	0.08
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Options forfeited/cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	0.71
Share-based Payment Arrangement, Option [Member] \| Minimum [Member]
Exercise Price per Share, Outstanding as of December 31, 2019	0.61
Exercise Price per Share, Granted	0.001
Exercise Price per Share, Exercised
Exercise Price per Share, Options forfeited/cancelled
Exercise Price per Share, Outstanding as of September 30, 2020	0.001
Share-based Payment Arrangement, Option [Member] \| Maximum [Member]
Exercise Price per Share, Outstanding as of December 31, 2019	1.21
Exercise Price per Share, Granted	0.31
Exercise Price per Share, Exercised
Exercise Price per Share, Options forfeited/cancelled
Exercise Price per Share, Outstanding as of September 30, 2020	$ 1.21

STOCK OPTION PLAN AND STOCK-B_6

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details 3)	9 Months Ended
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details 3)	Sep. 30, 2020USD ($)$ / sharesshares
Exercise Price, Lower Range Limit	$ 0.001
Exercise Price, Upper Range Limit	$ 1.21
Options Outstanding, Number of Options \| shares	485,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.71
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 1 month 6 days
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	485,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.71
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 1 month 6 days
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 0.001 [Member]
Options Outstanding, Number of Options \| shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.001
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 6 months 29 days
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.001
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 6 months 29 days
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 0.31 [Member]
Options Outstanding, Number of Options \| shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.31
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 3 months
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.31
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 3 months
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 0.95 [Member]
Options Outstanding, Number of Options \| shares	200,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.95
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 11 months 12 days
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	200,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.95
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	1 year 11 months 12 days
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 1.09 [Member]
Options Outstanding, Number of Options \| shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.09
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 9 months
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.09
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	1 year 9 months
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 1.10 [Member]
Options Outstanding, Number of Options \| shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.10
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 9 months 29 days
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.10
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	1 year 9 months 29 days
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 0.20 [Member]
Options Outstanding, Number of Options \| shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.20
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 9 months
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.20
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 9 months
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 0.32 [Member]
Options Outstanding, Number of Options \| shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.32
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 6 months
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.32
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 6 months
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 0.73 [Member]
Options Outstanding, Number of Options \| shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.73
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.73
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 0.15 [Member]
Options Outstanding, Number of Options \| shares	90,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.15
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 3 months 29 days
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	90,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.15
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 3 months 29 days
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 0.61 [Member]
Options Outstanding, Number of Options \| shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.61
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 29 days
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.61
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 29 days
Exercisable Options, Aggregate Intrinsic Value \| $
Exercise Price 1.21 [Member]
Options Outstanding, Number of Options \| shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.21
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 6 months 29 days
Options Outstanding, Aggregate Intrinsic Value \| $
Exercisable Options, Number of Options \| shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.21
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	1 year 6 months 29 days
Exercisable Options, Aggregate Intrinsic Value \| $

STOCK OPTION PLAN AND STOCK-B_7

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details 4) - Share-based Payment Arrangement, Option [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Number of Options, Non-vested as of December 31, 2019 \| shares
Number of shares, Granted \| shares	144,000
Number of Options, Non-vested Forfeited \| shares
Number of Options, Vested \| shares	(144,000)
Number of Options, Non-vested as of September 30, 2020 \| shares
Weighted-Average Grant-Date Fair Value, Non-vested as of December 31, 2019 \| $ / shares
Weighted-Average Grant-Date Fair Value, Granted \| $ / shares	0.11
Weighted-Average Grant-Date Fair Value, Forfeited \| $ / shares
Weighted-Average Grant-Date Fair Value, Vested \| $ / shares	0.11
Weighted-Average Grant-Date Fair Value, Non-vested as of September 30, 2020 \| $ / shares

STOCK OPTION PLAN AND STOCK-B_8

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details Narrative)	Sep. 17, 2020USD ($)shares	Aug. 03, 2020USD ($)shares	Aug. 01, 2020USD ($)$ / sharesshares	Jul. 02, 2020USD ($)$ / sharesshares	Jul. 02, 2020USD ($)Persons$ / sharesshares	May 01, 2020USD ($)$ / sharesshares	Apr. 02, 2020USD ($)$ / sharesshares	Feb. 02, 2020USD ($)$ / sharesshares	Jan. 02, 2020USD ($)shares	Jan. 02, 2020USD ($)$ / sharesshares	Mar. 18, 2020USD ($)$ / sharesshares	Feb. 21, 2020USD ($)Persons$ / sharesshares	Jan. 31, 2020USD ($)Persons$ / sharesshares	Mar. 25, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019shares	Dec. 31, 2010	Dec. 31, 2019shares
Number of shares issued, value \| $															$ 20,000
Stock-based compensation expense \| $																$ 228,058
Aggregate intrinsic value of options exercised \| $
Exercised \| shares																	293,000
2010 Stock Plan [Member]
Stock appreciation rights percentage																		15.00%
Options granted, value \| $									$ 257,143
Shares issued for services \| shares									1,127,000
Shares issued for services, value \| $									$ 864,551
Stock-based compensation expense \| $																$ 12,533
Weighted-average remaining contractual life options exercisable																2 years 1 month 6 days
Aggregate intrinsic value for fully vested, exercisable options \| $																$ 0
Aggregate intrinsic value of options exercised \| $																$ 0
Options or stock awards available for grant under the 2010 Plan \| shares																1,530,151
Equity Option [Member]
Options outstanding number \| shares									341,000	341,000
Share-based Payment Arrangement, Option [Member]
Options outstanding number \| shares																485,000			341,000
Number of shares, Granted \| shares																144,000
Grants in period, weighted average grant date fair value \| $ / shares																$ 0.11
Number of shares issued \| shares																293,000
Exercised \| shares
Mr. Mike Sheikh [Member] \| Share-based Payment Arrangement, Option [Member]
Number of shares issued \| shares						8,800,000
Number of shares issued, value \| $						$ 8,800
Share price \| $ / shares						$ 0.001
Weighted-average remaining contractual life options exercisable						3 years
Medical Advisory Board [Member] \| Share-based Payment Arrangement, Option [Member]
Number of shares, Granted \| shares			45,000	3,000		45,000	3,000	45,000		3,000
Grants in period, weighted average grant date fair value \| $ / shares			$ 0.14	$ 0.18		$ 0.001	$ 0.32	$ 0.15		$ 0.31
Options granted, value \| $			$ 6,300	$ 538		$ 45	$ 646	$ 4,401		$ 603
Terms of award			Three-year options	Three-year options		Three-year options	Three-year options	Three-year options		Three-year options
Consultant [Member]
Number of shares, Granted \| shares										250,000	200,000
Grants in period, weighted average grant date fair value \| $ / shares										$ 0.285	$ 0.245
Options granted, value \| $										$ 71,250	$ 49,000
Members Audit Committee [Member]
Number of shares, Granted \| shares												3,000
Grants in period, weighted average grant date fair value \| $ / shares												$ 0.439
Number of persons \| Persons												3
Options granted, value \| $												$ 1,317
Board of Directors Chairman [Member]
Number of shares, Granted \| shares					3,000									3,000
Grants in period, weighted average grant date fair value \| $ / shares					$ 0.19									$ 0.31
Number of persons \| Persons					3
Options granted, value \| $					$ 570									$ 930
Medical Consultants [Member]
Number of shares, Granted \| shares	50,000	100,000
Options granted, value \| $	$ 1,500	$ 300
Subcontractors [Member]
Number of shares, Granted \| shares													200,000
Grants in period, weighted average grant date fair value \| $ / shares													$ 0.14
Number of persons \| Persons													2
Options granted, value \| $													$ 28,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Sep. 30, 2020	Jun. 05, 2020
Payment of severance upon termination	$ 100,000
Power Up #1 [Member]
judgment for an amount of not less		$ 420,750

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Nov. 01, 2020	Oct. 01, 2020	Sep. 30, 2020
Option term			3 years
Subsequent Event [Member] \| 2010 Stock Plan [Member]
Number of shares, Granted		3,000
Exercise price		$ 0.02
Fair value		$ 60
Subsequent Event [Member] \| 2010 Stock Plan [Member] \| Medical Advisory Board Member [Member]
Number of shares, Granted	45,000	3,000
Option term	3 years	3 years
Exercise price	$ 0.18	$ 0.05
Fair value	$ 5,792	$ 135

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details 4) - Share-based Payment Arrangement, Option [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Number of Options, Non-vested as of December 31, 2019 \| shares
Number of shares, Granted \| shares	144,000
Number of Options, Non-vested Forfeited \| shares
Number of Options, Vested \| shares	(144,000)
Number of Options, Non-vested as of September 30, 2020 \| shares
Weighted-Average Grant-Date Fair Value, Non-vested as of December 31, 2019 \| $ / shares
Weighted-Average Grant-Date Fair Value, Granted \| $ / shares	0.11
Weighted-Average Grant-Date Fair Value, Forfeited \| $ / shares
Weighted-Average Grant-Date Fair Value, Vested \| $ / shares	0.11
Weighted-Average Grant-Date Fair Value, Non-vested as of September 30, 2020 \| $ / shares